Navigation Links
Secretropin(R) - Effective, Preferable, Affordable as an Alternative to Injectable Growth Hormone - Gains Momentum
Date:2/2/2009

ENCINO, Calif., Feb. 2 /PRNewswire/ -- Secretropin(R), the first clinically proven natural stimulator of growth hormone production, is gaining the medical community's acceptance as a more desirable "first step" approach to pursuing hormonal balance. Although classified as a natural food supplement, Secretropin(R) is only available through a prescribing physician due to its clinically proven ability to increase the body's own production and release of growth hormone. This reproducible response of Secretropin's(R) use is reflected in its recently posted 9-month retail sales record of $1M.

Developed in 2001, Secretropin(R) received early medical acknowledgement for 2 key reasons: one, its reproducible effectiveness; and two, its preferable oral delivery. In as little as 4 weeks Secretropin(R) has been shown to increase the production of growth hormone by 50 - 200% while being delivered as an oral spray. Secretropin's(R) oral delivery system (ODS) owes its effectiveness to the latest nanoliposomal technology, which wraps the active agents in a protective envelop. Until this delivery technology was available, stomach acid would inactivate and destroy the active agents responsible for the increase in growth hormone production.

Prior to Secretropin(R), this left injectable growth hormone as the only other viable option. Fortunately, the nanoliposomal technology protects the complex, allowing for optimal absorption and leading to a more natural increase in growth hormone levels - thus eliminating the less desirable approach of daily injections.

On the financial side, the present global market for injectable human growth hormone (HGH) therapy is estimated to exceed $3B. The market is growing at a projected 15 to 20% rate as the world medical community recognizes the benefits to maintaining healthy hormone levels throughout life. Currently, injectable GH therapy costs approximately $1000/month, and with the technological advances captured by Secretropin(R), the cost range has been significantly reduced to between $150 and $200/month.

The Millennium Health Center, Inc. participated in the development of Secretropin(R) and provides ongoing clinical research (report). As of October 2006, there are over 3000 patient months of data being compiled by a number of independent centers throughout the U.S., Australia, New Zealand, India, Russia, Thailand, China, and Dubai. So far, Secretropin's(R) ability to increase growth hormone production has been reported in excess of 95% of the cases.

The combination of known benefits of healthy levels of human growth hormone, plus Secretropin's(R) clinically documented response rate, added to its cost-effectiveness, is what is being labeled as a responsible first-step approach to pursuing age-appropriate hormonal balanced therapy.

    For additional information:

    Mark L. Gordon, M.D.
    Millennium Health Centers, Inc.
    Email: Info@secretropinrx.com

Website: http://www.secretropinrx.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Millennium Health Centers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
2. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
3. DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season
4. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
7. XTENT to Retain Investment Bank to Pursue Strategic Alternatives
8. N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency
9. New uses for imidazolium salts in medicine and alternative energy
10. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
11. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
Breaking Biology Technology:
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):